Podcasts about mcevoy

Send us a textIn this episode of The Incubator Podcast, we welcome Dr. Cindy McEvoy, Professor of Pediatrics and Director of Neonatal Research at OHSU, to discuss her work on the use of extended CPAP in preterm infants. CPAP has long been a cornerstone of neonatal care, but how long should stable infants remain on support? Dr. McEvoy shares findings from two randomized controlled trials that explored whether an additional two weeks of CPAP could promote lung growth and improve longer-term outcomes.We review the physiologic rationale behind extended CPAP, including the role of mechanical stretch in stimulating alveolar and vascular development. Dr. McEvoy explains the stability criteria used to determine eligibility for extended CPAP and how her team measured pulmonary function in neonates. Results from her studies showed significant improvements in lung volume, diffusion capacity, and expiratory flows, with early signals of reduced wheezing at one year of age.The conversation also touches on feeding tolerance, the practicalities of implementing extended CPAP in the NICU, and the need for larger multicenter studies to confirm these findings. This episode offers an evidence-based look at how a simple extension of an existing therapy might reshape respiratory outcomes for preterm infants.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

Aussie sprinter Jamie Jack made noise at the 2025 US Summer Championships in Irvine last week. On day 1, he took victory in the 50 free over US Olympians Hunter Armstrong, Caeleb Dressel, and Brooks Curry, posting matching 21.63s in prelims and the final. But Jack still thought there was more in the tank. Taking a day of rest on Day 2, he time trialed the 50 free on Day 3, swimming a 21.43 to make him the 5th fastest Australian man in history and tie for 4th in the world this season. After returning home, Jack sat down with SwimSwam to discuss his season between Australian Trials, where he was 21.8, and US Champs. The SPW product said he discussed a plan with coach Dean Boxall that focused just on the 50 free (only for the rest of the season). That also included training with Cam McEvoy and his coach, Tim Lane, in the lead-up to Irvine.

In this episode, Glen Sutherland is joined by his personal accountant, Kristopher McEvoy, a Canadian CPA specializing in cross-border taxation. Kristopher works with clients investing in U.S. real estate, as well as those relocating or expanding businesses between Canada and the U.S. The discussion centers around a frequently asked question: what's the most efficient way for Canadians to pay themselves from their U.S. real estate or business income? Kristopher explains that the answer depends on the ownership structure: If using a U.S. Limited Partnership (LP): You're taxed annually on profits—not on withdrawals—so taking money out has no further tax consequences. If using a U.S. Corporation: Paying yourself personally via dividends or payroll can be highly tax inefficient, with a potential combined tax burden of up to 50–60%. A more efficient strategy involves using a Canadian corporation to own the U.S. corporation, enabling: Management fees Interest charges Intercompany dividends (typically subject to only 5% U.S. withholding tax under the current tax treaty)

In hour three, Mike & Jason chat with BC Lions Vice President of Football Operations Neil McEvoy (2:00) about what the Leos need to do get back in the win column, as they look to exact their revenge on Hamilton at their next matchup on Thursday August the 7th, plus the boys tell us what they learned (27:00). This podcast is produced by Andy Cole and Greg Balloch. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

Was wäre wenn …? Hätte ich doch nur … Müsste ich nicht eigentlich…? Das kennt wahrscheinlich jeder von uns: Gedanken, die immer wieder um dieselben Themen kreisen. Man kommt nicht runter vom Gedankenkarussell. Wiederkehrende, belastende Gedanken sind ein zentrales Merkmal vieler psychischer Belastungen. In dieser Folge fragen sich Atze und Leon, warum wir dazu neigen, in solchen Denkschleifen zu verharren und werfen einen Blick auf aktuelle Forschungsansätze und evidenzbasierte Strategien zum Grübeln. Was ist normal und was ist schon nicht mehr gesund? Und was können wir konkret im Alltag tun, um das Gedankenkarussell zu stoppen? Fühlt euch gut betreut Leon & Atze Instagram: https://www.instagram.com/leonwindscheid/ https://www.instagram.com/atzeschroeder_offiziell/ Mehr zu unseren Werbepartnern findet ihr hier: https://linktr.ee/betreutesfuehlen Tickets: Atze: https://www.atzeschroeder.de/#termine Leon: https://leonwindscheid.de/tour/ VVK Münster 2025: https://betreutes-fuehlen.ticket.io/ Quellen: Review zu RNT & Transdiagnostik: Moulds, M. L., & McEvoy, P. M. (2025). Repetitive negative thinking as a transdiagnostic cognitive process. Nature Reviews Psychology, 1-15. https://www.nature.com/articles/s44159-024-00399-6 Übersichtsartikel über die Forschung von Susan Nolen-Hoeksema: Lyubomirsky, S., Layous, K., Chancellor, J., & Nelson, S. K. (2015). Thinking about rumination: The scholarly contributions and intellectual legacy of Susan Nolen-Hoeksema. Annual review of clinical psychology, 11(1), 1-22. https://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-032814-112733 Teismann, T., & Ehring, T. (2019). Pathologisches Grübeln (Vol. 74). Hogrefe Verlag GmbH & Company KG. Watkins, E. D., Moulds, M., & Mackintosh, B. (2005). Comparisons between rumination and worry in a non-clinical population. Behaviour research and therapy, 43(12), 1577-1585. Praktische Tipps: Wignall, N. (2020). 10 Simple Ways to Stop Overthinking Everything. https://nickwignall.com/overthinking/ Becker, E. S., & Margraf, J. (2008). Vor lauter Sorgen.... Hilfe für Betroffenen von Generalisierter Angststörung (GAS) und deren Angehörige. Weinheim: Beltz. Wahl, K., Ehring, T., Kley, H., Lieb, R., Meyer, A., Kordon, A., ... & Schönfeld, S. (2019). Is repetitive negative thinking a transdiagnostic process? A comparison of key processes of RNT in depression, generalized anxiety disorder, obsessive-compulsive disorder, and community controls. Journal of behavior therapy and experimental psychiatry, 64, 45-53. Querstret, D., & Cropley, M. (2013). Assessing treatments used to reduce rumination and/or worry: A systematic review. Clinical psychology review, 33(8), 996-1009. Wang, S., Lu, M., Dong, X., & Xu, Y. (2025). Does physical activity-based intervention decrease repetitive negative thinking? A systematic review. PLoS One, 20(4), e0319806. Repetitive Negative Thinking transdiag. zu betrachten, ist als Idee nichtneu: 2 Reviews kommen auch schon zu diesem Schluss: Ehring, T., & Watkins, E. R. (2008). Repetitive negative thinking as a transdiagnostic process. International journal of cognitive therapy, 1(3), 192-205. Harvey, A. G., Watkins, E., Mansell, W., & Shafran, R. (2004). Cognitive behavioural processes across psychological disorders. Oxford, UK: Oxford University Press Die Geschichte der Reagans: https://www.spiegel.de/geschichte/attentat-auf-ronald-reagan-a-947145.html https://www.latimes.com/local/obituaries/la-me-joan-quigley-20141024-story.html https://www.nytimes.com/2014/10/25/us/joan-quigley-astrologer-to-a-first-lady-is-dead-at-87.html Redaktion: Andy Hartard Produktion: Murmel Productions

In hour two, Mike & Jason discuss what next moves might come for the Canucks this off-season (3:00), plus they chat with BC Lions Vice President of Football Operations Neil McEvoy (24:39) ahead of Saturday's matchup in Montreal. This podcast is produced by Andy Cole and Greg Balloch. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

In this episode, Glen Sutherland and Kristopher McEvoy dive into the potential impact of proposed U.S. tax legislation on Canadian investors with U.S. assets. They discuss why proper investment structuring is more important than ever, the risks of increased withholding taxes, and how treaty changes could affect future returns. Kristopher shares why working with cross-border tax professionals is essential and offers practical strategies to help Canadians stay compliant, tax-efficient, and prepared for international policy shifts.

Samantha Dorsey, President of McEvoy Ranch, shares insights about the 550-acre certified organic property in Petaluma, California. The ranch, founded by Nan McEvoy, specializes in extra virgin and flavored olive oils while promoting sustainability and soil health. Watch the rest of the IOC series to learn more about this permanent crop from a diverse group of olive oil experts, chefs, scientists and growers. Find recipes, videos and more information at https://www.plantforwardkitchen.org/olive-oil-and-the-plant-forward-kitchen

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Timing of BP Meds – The BedMed RCT MAPEC https://doi.org/10.3109/07420528.2010.510230 Hygia https://doi.org/10.1093/eurheartj/ehz754 Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501 TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860 Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2 Timing of Blood Pressure Meds Doesn't Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm II Tirzepatide vs Semaglutide SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 III Age-specific Troponins Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308 Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967 IV Return to Play for Gene Positive Phenotype Negative athletes Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013 V Rapid Titration of GDMT in HF STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698 JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020 STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1 AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474 EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

One week into the Kamloops fun, Matt and Nik break down key camp battles shaping up and react to the exciting news of Snoop Dogg performing 2025 Concert Kickoff. VP of Football Operations Neil McEvoy joins the show to give a perspective on how the roster is shaping up and some camp memories from years past with the team. The fellas also bring our always-entertaining 'Go For It Or Punt' and 'They Not Like Us' segments, plus introduce Between The Lines with Cam Tucker from BCLC! 0:00 - Intro 1:11 - Snoop Dogg performing at Concert Kickoff 3:36 - Training Camp updates 14:21 - Between The Lines with Cam Tucker of PlayNow 25:06 - Neil McEvoy interview 44:56 - Go For It Or Punt 48:56 - They Not Like Us

Fat-Obese…50%+ of Humans are - Who to blame? Description… Fat-Obese…50%+ of Humans are - Who to blame? Is it the fast food folks, the fizzy drink makers, chocolate, genetics, depression? Can we fix this worldwide, “growing” challenge? If yes- HOW? www.maxfitnesscollege.com

Fastest Way to Get Fit and Strong? Is there a best way, and if yes, will it work for everyone? How to get and stay healthy, fit and strong for a lifetime? www.maxfitnesscollege.com

“You are NOT Good Enough” – Why do we believe that? Are you living your passion, enjoying your talent, gifts and creativity? OR have you let people steal your dream? www.maxfitnesscollege.com

AI, Robots, Technology…Will they make us healthier, fitter, stronger, wiser? What happens to our self-esteem, self-worth, sense of accomplishment if we don't create or achieve it?

Mums…Are You a Healthy, Happy Mum for Your Kids? Will your kids be inspired to be healthy, fit, strong, energetic, happy, and motivated because you are? www.maxfitnesscollege.com

Your business or Career…How to Earn More Money? The simple, free way to increase profit, customer/client/member retention, and referrals www.maxfitnesscollege.com

Guilt - Can it be motivation? If you hate feeling guilty for procrastinating, failing, stopping, what is the best way to get rid of that guilty feeling? www.maxfitnesscollege.com

Your Hobby - Your Passion…How to turn it into your profitable career? And you CAN!! www.maxfitnesscollege.com

Motivation and Inspiration HOW TO get and keep them? If you need somebody to inspire you, motivate you, or hold you accountable- what if they don't show up? www.maxfitnesscollege.com

What is the Best Exercise Equipment? What is the best way to exercise? What is the best way to exercise for your time and $$ investment?

Stress- We could die without it!! WHY and HOW? How to handle, deal with, even love and be thankful for ALL stress? HOW?

Your last 20 years…What do you want them to be like?: Description… Your last 20 years…What do you want them to be like? Do we have to be fat, sick, weak, frail, diseased? OR can we make sure we are healthy, fit, strong, lean, energetic and have great quality of life? www.maxfitnesscollege.com

Wrong or Right? Good or Bad? Is there Grey? Is it possible we get what we accept? Is there really average or grey for your health, relationships, finances or career? www.maxfitnesscollege.com

Excess Fat, Weight, Baggage… in your brain or on your body, why do we carry around baggage that holds us back and slows down or stops our success- how to drop it off? www.maxfitnesscollege.com

Food… A Guilt or Pleasure Experience for you? Do you want to eat all the things you love without feeling guilty? www.maxfitnesscollege.com

Fat, Tired, Unfit, Unhealthy…The fastest way to change? Can we be healthy, fit, strong, and lean for life? If yes- HOW? In NO- what are the consequences/risks? www.maxfitnesscollege.com

Fat, Broke, Unhealthy, Unhappy…Who to Blame? Who has eaten, spent, chosen, and decided all the things I have done in my life up until now? If I am not healthy, fit and strong, financially free and happy, who can I blame versus what do I need to change? www.maxfitnesscollege.com

Exercise...How much is too much or a waste of time? What is the tiniest amount of exercise we can do to be fittest, strongest, healthiest and LEANEST? www.maxfitnesscollege.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

In October 2022 at the age of 20, Laura McEvoy from Northern Ireland was involved in a devastating car accident that changed her life forever, leaving her with a spinal cord injury at L1, fractured vertebrae in her neck, and a cracked skull. Told she might never walk again, Laura refused to accept defeat. Through sheer determination and the unwavering support of her family and friends, she defied the odds rebuilding her life step by step facing life's toughest challenges with remarkable resilience and passion.  A former competitive Irish dancer and outdoor enthusiast, Laura found her way back to the activities she loved and discovered new passions along the way. From learning to walk again with crutches and AFOs to abseiling and climbing the iconic Rathlin Wall at Fairhead, she has redefined what it means to overcome adversity. Today, Laura is a passionate advocate for accessible outdoor adventure, working with organisations including; Mountaineering Ireland, Tollymore, and Accessible Adventures Ireland to create inclusive opportunities in climbing, paddle sports and hiking. She's raised thousands for The Outdoor Partnership, earned multiple climbing qualifications, and is now leading the way in organising major inclusive and adaptive expeditions, this past weekend she was part of a paddling and camping adventure on Lough Erne.  As if that wasn't enough, Laura is also making her mark on the court as a wheelchair basketball athlete for Northern Ireland, with her sights set firmly on the Commonwealth Games in 2026. Her motto, "Say yes to everything," captures the spirit of a woman who isn't just surviving trauma she's thriving and inspiring others to believe that their limits are only the starting point.

Are you stuck in a job you hate? Have you given up on your dream career? WHY? Is it time to wake up doing what you LOVE every day? How to do it… www.maxfitnesscollege.com

What to Eat? Meat? Plants? Supplements? WHY? How do you know what the best way for YOU to eat? www.maxfitnesscollege.com

How to Lose Weight and Never Find It Again? How to be lean, fit, strong, healthy, and energetic for a lifetime www.maxfitnesscollege.com

Can you handle life's tough stuff? Is your body and brain ready to drive on life's bumpy, tough, hard roads? AND arrive stronger, better and wiser? www.maxfitnesscollege.com

Problems…Do we cause them, or are we unlucky? Regardless of where they come from, how to get mentally tough, fit and strong to overcome all challenges, and always be the solution-finder www.maxfitnesscollege.com

Unhealthy or Unhappy…Is it time to make changes? What to do- How and when? www.maxfitnesscollege.com

Water…What if 8 glasses is not enough or too much? What size glasses? What if you move more, sweat more, or a tiny or bigger person? www.maxfitnesscollege.com

Untidy, Dirty, Disorganised…Does it Matter? Could it be easier to be successful if your home, office, car, headspace is clean of junk? www.maxfitnesscollege.com

Age versus how many more fun times do we have left in our life? We are all getting older but how many great memories are we creating every day so we remember EVERY day, month, year and SEASON? www.maxfitnesscollege.com

Welcome to a Wide World of Sports update. A snapshot of the latest sport stories from the 9News team including: Coach McGuire eyes off "opportunity" against ladder-leaders Dees boosted by key inclusions for MCG battle with Tigers McKeown, McEvoy & Temple shine in the pool The biggest sport stories in less than 5 minutes delivered twice a day, with reports from the 9News team across Australia and overseas. Subscribe now to make it part of your daily news diet. See omnystudio.com/listener for privacy information.

Exercise…Why do men get leaner-faster? Can women speed up their metabolism to burn fat/food/calories as fast as men? If yes- HOW? www.maxfitnesscollege.com

Hormones…Can we control them? Our weight, metabolism, health, emotions, mental health, critical thinking, happiness; if we control our hormones could we be in control of all of these? www.maxfitnesscollege.com

“Light Weights for Toning”…What if that really means train with little light weights and you have more chance of getting injured, you will be wasting time and getting no results? Is it time to drop the “Namby Pamby” weights and lift heavy to overload and get results FAST? www.maxfitnesscollege.com

Failing…Can we STOP? Can we choose to succeed? YES/NO/Why? www.maxfitnesscollege.com

Your Body…Is it stopping you from doing the fun stuff? Are you healthy, fit, strong, lean, and energetic- regardless of how old you are, so you CAN do ALL the Fun Stuff? If YES - Congratulations!! If NO - Is it time? www.maxfitnesscollege.com

Josh Sebo (COO of OfferVault), Adam Young (CEO of Ringba), industry legend Harrison Gevirtz and special guest Matt McEvoy (CEO of MaxBounty) discuss:- Medicarians 2025- MaxBounty Top Offers (eComm & Lead Gen)- Affiliate World Dubai (Highlights)- MaxBounty's Acquisition back in August 2024- Ultra 2025- Where do you see the industry headed in 2025 and beyond?Follow Us:OfferVault:WEBSITE: https://www.offervault.com/FACEBOOK: https://www.facebook.com/offervaultINSTAGRAM: https://www.instagram.com/offervaultmarketing/TWITTER: https://www.twitter.com/offervaultLINKEDIN: https://www.linkedin.com/company/offer-vault/Adam Young: RINGBA: https://www.ringba.comRINGBA's INNER CIRCLE: https://try.ringba.com/inner-circle/FACEBOOK: https://www.facebook.com/ringbaINSTAGRAM: https://www.instagram.com/adamyoung/TWITTER: https://www.twitter.com/arbitrageLINKEDIN: https://www.linkedin.com/in/capitalistHarrison Gevirtz:INSTAGRAM: https://www.instagram.com/affiliate/LINKEDIN: https://www.linkedin.com/in/harrisongevirtz/Matt McEvoy:MAXBOUNTY: https://maxbounty.com/INSTAGRAM: https://www.instagram.com/matt.mcevoy31/LINKEDIN: https://www.linkedin.com/in/mattmcevoy/

BROUGHT TO YOU BY M.L. ROSE Find a location near you at https://mlrose.com/ Sponsored by SINKERS BEVERAGES AND BLUEGRASS BEVERAGE Check Them Out HERE: https://sinkersbeverages.com/ ______________________________ Tips? Thoughts? Comments? Suggestions? Email the show here: jtruhnkebsm1@gmail.com Subscribe to The Hot Read Podcast here: Apple: https://apple.co/3eGTlel Spotify: https://spoti.fi/3d2UcW4 Follow us on social media! Instagram: https://tinyurl.com/2s3v9dcw TikTok: https://tinyurl.com/mya8kpme The Hot Read Podcast on Twitter: https://tinyurl.com/5238x3c9 JT Ruhnke on :Twitter: https://tinyurl.com/2p8wj389 Stoney Keeley on Twitter: https://tinyurl.com/ms7a57ty 440 Sports on Twitter: https://tinyurl.com/yey432v9 #Titans #TennesseeTitans #Tennessee #NFL #AFC # AFCSouth #NFLhighlights #reaction #Titansnews #WillLevis #Levis #analysis #predictions #NFLbetting #Fantasyfootball #Titansmedia #Titanspractice #Football #TennesseeForever

Well Dash Hounds, if you are still out there listening and tuning in, we are thankful. Listening is an act of love. Love brings joy, and joy is a form of resistance. So sit back this week and learn how Kelly and Beth are getting through the hard times naturally. Of course with everything that seems good, be cautious. Nature is such a healer until it isn't. And it's just you and your houseplant whose picking up on your negative vibes and blaming you for everything. Confused? So are we. Theme music: Big White Lie by A Cast of Thousands. Cite your sources, dude Eells, Josh. “He Talked to Plants and They Talked Back.” New York Times, 21 December 2017, https://archive.nytimes.com/www.nytimes.com/news/the-lives-they-lived/2013/12/21/cleve-backster/. First, Elsa. “The Secret Life of Plants.” New York Times, 30 December 1973, https://www.nytimes.com/1973/12/30/archives/the-secret-life-of-plants-by-peter-tompkins-and-christopher-bird.html. Fitzgerald, Sunny. “The Secret to Mindful TRavel: A Walk in the Woods.” National Geographic, vol. October, 2019, https://www.nationalgeographic.com/travel/article/forest-bathing-nature-walk-health. McEvoy, Patrick. “Courage, Memory and Voice: A Review of Monica Gagliano's Thus Spoke the Plant.” Ecological Citizen, https://www.ecologicalcitizen.net/pdfs/v04n1-13.pdf. Schreiber, Dan. The Theory of Everything Else: A Voyage Into the World of the Weird. HarperCollinsPublishers, 2023. Stempel, Jonathan, and Husch Blackwell. “Apple to pay $95 million to settle Siri privacy lawsuit.” Reuters, 2 January 2025, https://www.reuters.com/legal/apple-pay-95-million-settle-siri-privacy-lawsuit-2025-01-02/. Accessed 20 January 2025.

In the 872nd episode of the PokerNews Podcast, which kicks off the New Year and Season 16, Chad Holloway, Kyna England, and Mike Holtz are all at Level 9 Studio in Las Vegas to recap some of the biggest stories from the poker world in 2024. That includes GGPoker purchasing the World Series of Poker (WSOP), both Daniel Negreanu and Phil Ivey capturing WSOP gold bracelets, poker bots, and Kristen Foxen's remarkable year, which included a deep run in the WSOP Main Event and being inducted into the Women in Poker Hall of Fame. Other stories they touch upon include Nick Vertucci's departure from Hustler Casino Live (HCL), the summer of Scott Seiver, and Triton Poker hitting it out of the park. Chad then shares a special one-on-one interview he did with 1983 WSOP Main Event champ and Poker Hall of Famer Tom McEvoy to talk about his autobiography Poker Pioneer. McEvoy talks about the biggest moments of his storied career, shows off his extensive poker collection, and shares stories of some of the biggest names in poker including Doyle Brunson, Stu Ungar, and Phil Ivey, just to name a few. When it comes to poker history, few have as much experience as McEvoy, and this is your chance to hear from someone who actually lived it. The podcast is sponsored by the #1 free-to-play WSOP app. Remember to use bonus code "POKERNEWS" if you download and play for an extra 1,000,000 in chips! A new PokerNews Podcast will drop weekly every Friday at 8a PT / 11a ET / 4p UK time. Remember to subscribe to our YouTube channel so you do not miss an episode! Time Stamps *Time | Topic* 00:08 | Welcome Kyna England & Mike Holtz 01:03 | Top Story #1 – GGPoker buys WSOP 04:46 | Top Story #2 – Negreanu & Ivey win bracelets 04:28 | Phil Ivey winner interview 07:50 | Top Story #3 – Bots, RTA & Laptopgate 14:03 | Top Story #4 – Kristen Foxen's WSOP Main Event run & Women in Poker Hall of Fame 15:40 | A look at Kristen Foxen's Women in Poker Hall of Fame trophy 16:38 | Top Story #5 – Debut of ClubWPT Gold & $5,000,000 Freeroll 18:15 | Nick Vertucci no longer with Hustler Casino Live 19:00 | Hand of the Year? Neymar vs. Alan Keating on HCL 20:20 | Scott Seiver wins three bracelets & POY at 2024 WSOP 21:57 | The return of PokerStars The Big Game 24:48 | Big year for Triton Poker 31:19 | Sponsor – WSOP Free-to-Play App 31:50 | Chad chats w/ Poker Hall of Famer Tom McEvoy 32:23 | New poker biography ‘Poker Pioneer' w/ Brad Smith 34:00 | Playing with fans in Ohio 40:36 | Being impressed by Phil Ivey & Erik Seidel 43:45 | Record for the longest heads-up match 47:07 | Having one of the largest and most impressive poker collections 51:04 | Poker Hall of Fame and the Smoking Petition 52:06 | The one time McEvoy almost got a penalty